Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update from the American College of Physicians
- MeSH Terms
Hemoglobin A; Glycosylated (D12.776.422.316.762.380.440); Hemoglobin A; Glycosylated (D12.776.124.400.405.440); Hemoglobin A; Glycosylated (D09.408.375); Diabetes Mellitus; Type 2 (C19.246.300); Therapeutic Uses (D27.505.954); Metformin (D02.078.370.141.450); Thiazolidinediones (D02.886.675.933); Dipeptidyl Peptidase 4 (D23.050.301.264.035.283); Diabetes Mellitus (C19.246); Drug Therapy; Combination (E02.319.310); Dipeptidyl-Peptidase IV Inhibitors (D27.505.696.422.500); Sodium-Glucose Transporter 2 (D12.776.157.530.500.750.750); Sodium-Glucose Transporter 2 (D12.776.543.585.500.750.750); Dipeptidyl-Peptidase IV Inhibitors (D27.505.519.389.745.335)
- Guideline Contact
- Amir Qaseem ([email protected])
- Publication Date
- 01/03/2017
- Date of Last Evidence Search
- 12/2015
- Methods Applied
- See Publication
- Publication Scope
- Treatment
- Countries of Application
- United States
- Guideline Publication Status
- Inactive
- Languages
- English
- Authors
- ACP (US)
- Publication Year
- 2017